Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nirmatrelvir + ritonavir - Pfizer

Next Previous
Drug Profile

Nirmatrelvir + ritonavir - Pfizer

Alternative Names: nirmatrelvir [PF-07321332] tablets and ritonavir tablets; Nirmatrelvir plus ritonavir - Pfizer; Nirmatrelvir+ritonavir - Pfizer; nirmatrelvir/ritonavir; PAXLOVID; PF 07321332 plus ritonavir - Pfizer; PF 07321332+ritonavir - Pfizer; PF-07321332/ritonavir

Latest Information Update: 28 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Amides; Amines; Antiretrovirals; Antivirals; Aza compounds; Carbamates; Fluorinated hydrocarbons; Heterocyclic bicyclo compounds; Nitriles; Pyrrolidinones; Small molecules; Thiazoles
  • Mechanism of Action Coronavirus 3C-like proteinase inhibitors; HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed COVID 2019 infections

Most Recent Events

  • 28 Mar 2025 No recent reports of development identified for phase-I development in COVID-2019-infections(In volunteers, In adults) in Belgium (PO)
  • 01 Nov 2024 Pfizer re-initiates the phase II/III EPIC-PEDS trial in COVID-2019 infections (In children, In adolescents, In infants, In neonates) in USA, Bulgaria, Hungary, Mexico, South Africa, United Kingdom (PO, Tablets) (NCT05261139) (EudraCT2022-000075-39)
  • 16 Oct 2024 Adverse events data from phase II/III EPIC-PEDS trial in COVID-2019 infections presented at IDWeek 2024 (IDW-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top